Custom Recombinant Protein Production Services Market 2018 | Industry In-depth Analysis By Players GenScript Biotech Corporation, Applied Biological Materials Inc., Eurofins Pharma Discovery Services, Abgent, OriGene Technologies, Inc., Crown Bioscience,

Recombinant proteins are used in development of novel therapies for severe chronic diseases such as cancer and other rare diseases. Recombinant protein production requires a special technique known as recombinant DNA (rDNA) technology. Recombinant proteins have immense potential in cancer therapy research and development. For instance, growth factors, immune checkpoint, and cell damage & oxidative stress proteins (preclinical stage) are utilized from recombinant proteins category for cancer therapy research.

Request Free Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2737

Market Dynamics

Increasing demand for recombinant proteins for basic research has supported growth of the custom recombinant protein production services market. Recombinant therapeutic proteins are one of the fast-growing areas in molecular medicine. Various biopharmaceutical companies are focusing on development of biologics and subsequently biosimilars. Moreover, increasing expenditure in research has supported the market growth. The R&D spending of the U.S. is around 2.7% of its Gross Domestic Products (GDP) with highest R&D investments observed in the biotechnology segment in 2014, according to American Pharmaceutical Review.

Moreover, major players in the market are focused on launching new facilities to cater to increasing demand for research and development, which is expected to drive the market growth. For instance, in 2016, ATUM established a new state-of-the-art bio-production facility in Newark, California, for rapid expansion and to provide better services to the customers.

However, high cost of protein expression systems and complex manufacturing procedures are the major factors restraining the market growth over the forecast period. For instance, the price of recombinant protein production services varies from US$ 500 to US$ 5000 per milligram depending upon the protein production expression systems, species of the proteins, and the family to which these recombinant proteins belong.

Increasing funding in the field of life sciences is expected to propel growth of the custom recombinant protein production services market

Recombinant protein is a manipulated form of protein, which is encoded by genes. It is used in production of large quantities of protein, which is further used for manufacturing of therapeutic commercial products. Increasing government initiatives and funding in the field of life sciences is expected to boost growth of the market. For instance, Life Sciences Greenhouse of Central Pennsylvania offers early stage funding of up to US$ 1-2 million in the form of convertible debt or equity financing to viable life sciences companies, which have significant potential for commercial growth.

Moreover, advancements in bioreactor systems have facilitated production of recombinant protein within shorter time span, which in turn is expected to propel growth of the custom recombinant protein production services market over the forecast period. For instance, according to National Centre for Biotechnology Information (NCBI), in 2014, around 65.6% of clinical scale manufacturers and 42% of commercial manufacturers adopted single-use bioreactors for improvement in their bioprocessing.

Increasing research and development and product launches in North America is expected to bolster the market growth

North America is expected to hold dominant position in the global custom recombinant protein production services market, owing to increasing focus of regional players in research and development and product launches. For instance, in 2014, Western Blot Service CRO, a division of Altogen Lab, launched automated WES protein analysis and protein expression services, providing a complete platform to conduct protein expression studies.

Moreover, the companies in the region are focused on adopting strategic acquisitions to expand their geographic presence. For instance, in 2017, Eurofins Scientific acquired DiscoverX to improve research productivity and accelerate the discovery and development of new drugs. The acquisition is also expected to create a robust portfolio of kinase products and services in the market.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2737

Key Players

Major players operating in the custom recombinant protein production services market include, GenScript Biotech Corporation, Applied Biological Materials Inc., Eurofins Pharma Discovery Services, Abgent, OriGene Technologies, Inc., Crown Bioscience, Inc., BPS Bioscience, Inc., ProteoGenix, Kempbio, Inc., Novoprotein, Premas Biotech, Trenzyme GmbH, Atum, Novus Biologicals, LLC, Icosagen AS, LakePharma, Inc., Proteos, Inc., Aldevron, and Sino Biological Inc.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.